RA CAPITAL MANAGEMENT, L.P. Portfolio
Auto-discovered 13F filer (Top-2000 by latest reported value).
SEC 13F CIK: 0001346824
What is a 13F filing? Who files one and when · What 13F filings can't tell you
Q2 2024 · 78 positions · Total reported value $7.56B · Top-10 concentration 53.9% · Updated 2026-10-18
Last updated: 2026-10-18 · Source: SEC EDGAR Form 13F-HR
Turnover: 38.4% · 15 new · 12 cut · 11 exited
Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking
Est. Qtr Return (Q2 2026 → Q3 2026): -13.6% · vs SPY -15.8% · Prev Value $11.51B — last quarter positions weighted by this quarter price moves · ranking
Est. QTD Return (Q3 2026 → newest close): -1.6% · vs SPY -3.7% · Latest Value $9.72B — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking
In its Q2 2024 13F filing, RA CAPITAL MANAGEMENT, L.P. disclosed 78 equity positions with a combined reported value of $7.56B. The filing implies a moderately concentrated portfolio: its ten largest positions account for 53.9% of reported value. HoldingsHub classifies the profile as Mid / Health Tilt / High Turnover.
The largest disclosed positions as of Q2 2024 were ASND ($1.38B), PCVX ($619.47M), JANX ($383.95M). By sector, the heaviest allocations are Health Care 84.2%, Consumer Discretionary 2.2%. Versus the prior quarter, allocation shifted toward Health Care (+2.0pp) and away from Industrials (-0.8pp), Other (-0.9pp).
Versus the prior quarter, RA CAPITAL MANAGEMENT, L.P. opened 15 new positions, trimmed 12 and fully exited 11, a turnover rate of 38.4% of positions. The portfolio's overlap with the prior quarter was 77% of names.
The largest new positions opened in Q2 2024 were RXRX ($115.38M), ACLX ($88.53M), TRML ($32.65M).
Of the 11 positions fully exited versus the prior quarter, the largest were INBX ($91.94M), MDGL ($54.61M), CTKB ($45.69M).
Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.
New Positions (Q2 2024)
- RXRX RECURSION PHARMACEUTICALS IN · $115.38M
- ACLX ARCELLX INC · $88.53M
- TRML TOURMALINE BIO INC · $32.65M
- NRIX NURIX THERAPEUTICS INC · $13.57M
- INSM INSMED INC · $13.40M
- ZURA ZURA BIO LTD · $11.26M
- NUVL NUVALENT INC · $9.09M
- PCSC PERCEPTIVE CAP SOLUTIONS COR · $7.54M
Fully Exited (vs previous quarter)
- INBX INHIBRX BIOSCIENCES INC · prev qtr: $91.94M
- MDGL MADRIGAL PHARMACEUTICALS INC · prev qtr: $54.61M
- CTKB CYTEK BIOSCIENCES INC · prev qtr: $45.69M
- VXRT VAXART · prev qtr: $20.00M
- EYPT EYEPOINT INC · prev qtr: $19.40M
- BDTX BLACK DIAMOND THERAPEUTICS I · prev qtr: $17.88M
- IGMS IGM BIOSCIENCES INC · prev qtr: $9.05M
- CMPS COMPASS PATHWAYS PLC · prev qtr: $6.58M
Insider Transactions (Form 4)
Latest RA CAPITAL MANAGEMENT, L.P. buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.
| Transaction date | Activity | Security | Shares | Price | Filing |
|---|---|---|---|---|---|
| 2026-11-02 | Buy | Bambusa Therapeutics, Inc. | 164,891 | $16.00 | SEC filing |
| 2026-11-02 | Buy | Bambusa Therapeutics, Inc. | 2,335,109 | $16.00 | SEC filing |
| 2026-11-02 | Conversion | Bambusa Therapeutics, Inc. | 1,331,080 | — | SEC filing |
| 2026-11-02 | Conversion | Bambusa Therapeutics, Inc. | 3,144,858 | — | SEC filing |
| 2026-10-30 | Buy | Bambusa Therapeutics, Inc. | 263,911 | $14.92 | SEC filing |
| 2026-10-30 | Buy | Bambusa Therapeutics, Inc. | 189,909 | $14.23 | SEC filing |
| 2026-10-29 | Sell | LENZ Therapeutics, Inc. | 107,170 | $3.36 | SEC filing |
| 2026-10-29 | Sell | LENZ Therapeutics, Inc. | 451,998 | $3.36 | SEC filing |
Fund Profile
RA Capital Management is a Boston-based investment firm founded by Peter Kiernan, specializing in healthcare-focused investments with a long-term, value-oriented approach.
Investment Approach
Focuses on healthcare sector investments
Long-term, value-oriented strategy
Deep fundamental research and analysis
Asset Classes & Strategy
Primarily invests in public equities
Also manages private investments in healthcare companies
Concentrated portfolio approach with significant positions in healthcare companies
Key Personnel
Peter Kiernan: Founder and portfolio manager
Team of experienced investment professionals with healthcare expertise
Notable Facts
Founded in 2002
Manages approximately $16.4 billion in assets
Files SEC Form 13F for US equity positions
This profile is based on publicly available information and should not be considered as official disclosure from the firm.
| # | Company | Shares | Value | Weight | Allocation | Change |
|---|---|---|---|---|---|---|
| 1 |
|
10.11M | $1.38B | 18.23% | Hold | |
| 2 |
|
8.20M | $619.47M | 8.19% | Hold | |
| 3 |
|
9.17M | $383.95M | 5.08% | Hold | |
| 4 |
|
7.51M | $332.48M | 4.40% | Add | |
| 5 |
|
6.08M | $249.83M | 3.30% | Add | |
| 6 |
|
982.14K | $227.68M | 3.01% | Add | |
| 7 |
|
31.42M | $223.39M | 2.96% Form 4 · 4 → |
Add | |
| 8 |
|
3.69M | $222.32M | 2.94% | Add | |
| 9 |
|
5.40M | $220.61M | 2.92% | Add | |
| 10 |
|
6.05M | $213.48M | 2.82% | Add | |
| 11 |
|
46.20M | $195.90M | 2.59% | Hold | |
| 12 |
|
10.69M | $170.61M | 2.26% | Hold | |
| 13 |
|
10.42M | $166.56M | 2.20% | Hold | |
| 14 |
|
8.51M | $162.80M | 2.15% | Add | |
| 15 |
|
8.91M | $160.45M | 2.12% | Hold | |
| 16 |
|
8.06M | $154.91M | 2.05% | Add | |
| 17 |
|
15.38M | $115.38M | 1.53% | New | |
| 18 |
|
14.18M | $113.54M | 1.50% | Add | |
| 19 |
|
7.63M | $110.37M | 1.46% | Add | |
| 20 |
|
7.87M | $108.47M | 1.44% | Add | |
| 21 |
|
5.10M | $107.01M | 1.42% | Add | |
| 22 |
|
10.86M | $92.43M | 1.22% | Hold | |
| 23 |
|
18.20M | $90.83M | 1.20% Form 4 · 1 → |
Hold | |
| 24 |
|
3.29M | $88.90M | 1.18% | Hold | |
| 25 |
|
1.60M | $88.53M | 1.17% | New | |
| 26 |
|
1.00M | $80.50M | 1.06% | Hold | |
| 27 |
|
1.96M | $77.20M | 1.02% | Reduce | |
| 28 |
|
6.60M | $76.98M | 1.02% | Add | |
| 29 |
|
1.90M | $74.49M | 0.98% | Add | |
| 30 |
|
4.18M | $72.25M | 0.96% Form 4 · 3 → |
Hold | |
| 31 |
|
11.61M | $71.98M | 0.95% | Hold | |
| 32 |
|
10.81M | $63.86M | 0.84% | Hold | |
| 33 |
|
2.33M | $60.38M | 0.80% | Hold | |
| 34 |
|
4.85M | $56.76M | 0.75% | Hold | |
| 35 |
|
3.52M | $52.20M | 0.69% | Reduce | |
| 36 |
|
3.08M | $51.74M | 0.68% | Hold | |
| 37 |
|
1.24M | $51.10M | 0.68% | Add | |
| 38 |
|
2.12M | $49.60M | 0.66% | Hold | |
| 39 |
|
8.34M | $48.37M | 0.64% | Add | |
| 40 |
|
5.04M | $45.90M | 0.61% | Add | |
| 41 |
|
2.25M | $45.60M | 0.60% | Add | |
| 42 |
|
1.40M | $44.12M | 0.58% | Hold | |
| 43 |
|
6.05M | $43.83M | 0.58% | Hold | |
| 44 |
|
14.93M | $36.14M | 0.48% | Hold | |
| 45 |
|
2.54M | $32.65M | 0.43% | New | |
| 46 |
|
2.03M | $26.43M | 0.35% | Hold | |
| 47 |
|
4.33M | $24.55M | 0.33% | Hold | |
| 48 |
|
10.87M | $24.35M | 0.32% | Hold | |
| 49 |
|
7.62M | $23.63M | 0.31% | Add | |
| 50 |
|
22.75M | $22.75M | 0.30% Form 4 · 1 → |
Hold | |
FAQ
What did RA CAPITAL MANAGEMENT, L.P. buy in 2024-Q2?
In its 2024-Q2 13F filing, RA CAPITAL MANAGEMENT, L.P. reported 78 equity positions worth $7.56B in aggregate; its largest disclosed positions were ASND ($1.38B), PCVX ($619.47M), JANX ($383.95M).
How large is RA CAPITAL MANAGEMENT, L.P.'s portfolio?
RA CAPITAL MANAGEMENT, L.P. reported $7.56B of long equity holdings across 78 positions as of 2024-Q2. Top-10 holdings account for 53.9% of reported value.
What is RA CAPITAL MANAGEMENT, L.P.'s investment style?
HoldingsHub classifies the portfolio as Mid / Health Tilt / High Turnover, computed from size, concentration, sector tilt and turnover.
Where does this data come from?
All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.